Rate and characteristics of inflammatory neuropathies associated with brentuximab vedotin therapy.
Arthur MatthysBenjamin BardelFabien Le BrasAlain CréangeTarik NordineRomain GounotSaskia Ingen-Housz-OroMuriel CarvalhoJean-Pascal LefaucheurCorinne HaiounViolaine Planté-BordeneuveThierry GendrePublished in: European journal of neurology (2024)
Brentuximab vedotin-induced neuropathy is an overlooked complication. Based on four easily identifiable "red flags", we provide an algorithm to help non-neurologist physicians that care for BV-treated patients to detect BV-IN. The aim of the algorithm is to decrease the diagnostic and management delay of this disabling neuropathy.
Keyphrases
- hodgkin lymphoma
- newly diagnosed
- end stage renal disease
- machine learning
- lipopolysaccharide induced
- healthcare
- ejection fraction
- chronic kidney disease
- palliative care
- prognostic factors
- oxidative stress
- high glucose
- stem cells
- diabetic rats
- neural network
- inflammatory response
- pain management
- bone marrow
- patient reported outcomes
- mesenchymal stem cells
- smoking cessation